期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌的新辅助化疗 被引量：1

乳腺癌的新辅助化疗
暂未订购
导出
摘要 乳腺癌已成为世界范围内最常见的女性恶性肿瘤,并且居女性癌症相关死亡病因的第2位。自1894年美国医生Halsted在约翰.霍普金斯医院开展第1例乳腺癌根治术至今,乳腺癌的治疗已有110年的历史。早在20世纪70年代,Fisher教授就提出了"乳腺癌是一种全身性疾病"的理念,随着近十几年来乳腺癌大宗病例的随访和分子生物学理论及技术的发展,国内外学者对这种理念才真正达成共识。尽管近年来,早期诊断、手术后放疗、化疗、内分泌治疗和分子靶向治疗等综合手段的应用,使乳腺癌病死率呈下降趋势,但乳腺癌的复发转移,尤其是远处转移仍然是困扰临床医生的最大难题。本期专门邀请了国内多位乳腺癌治疗专家,对乳腺癌的内科诊治进展进行探讨。
作者 谢晓冬 屈淑贤
机构地区 沈阳军区总医院肿瘤科
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2007年第24期1904-1907,共4页 Chinese Journal of Practical Internal Medicine
关键词 乳腺肿瘤 新辅助化疗 Breast neoplasms New adjuvant chemotherapy
分类号 R5 [医药卫生—内科学]
  • 相关文献

参考文献10

  • 1Fisher B, Guiduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases [ J ]. Cancer Ras, 1983,43 : 1488 - 1492.
  • 2Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer[J]. J Clin Oncol, 1998,16:2672 - 2685.
  • 3Jorgensen J, Cold S, Kamby C. Locally advanced breast cancer [J]. Ugeskr Laeger,2007,169(37 ) : 3091 - 3093.
  • 4Kuerer HM,Newman LA,Smith TL,et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy [ J ]. J Clin Oncol, 1999,17 ( 2 ) : 441 - 444.
  • 5Deo SV, Bhutani M, Shukla NK, et al. Randomized trial comparing neo-adjuvant verSus adjuvant chemotherapy in operable locally advanced breast cancer( T4b N0-2 M0)[ J ]. J Surg Oncol,2003,84 (4): 192-197.
  • 6von Minckwitz G,Raab G,Caputo A,et al. Doxorubicin with cyclo-phosphamide followed by doeetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group [ J ]. J Clin Oncol,2005,20,23 ( 12 ) : 2676 - 2685.
  • 7Prisack HB, Karreman C, Modlich O, et al. Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio) chemotherapy [ J ]. Anticancer Res ,2005,25 ( 6C ) :4615.
  • 8Kariya S,Ogaway Y,Nishioka A,et al. Relationship between hormonal receptors,HER-2,p53 protein ,Bcl-2,and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasire breast cancer patients[J]. Radiat Med,2005,23(3) :189.
  • 9刘非,刘健.乳腺癌新辅助化疗疗效预测因子研究进展[J].浙江中西医结合杂志,2006,16(8):528-530. 被引量：1
  • 10Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy:findings from the National Surgical Adjuvant Breast and Bowel(NSABP)protocol B-18[J]. Cancer,2002,95:681 -695.

二级参考文献21

  • 1Cristofanilli M,Gonzalez-Angulo A,Sneige N,et al. Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes. J Clin Oncol,2005,23:41
  • 2Prisack HB, Karreman C, Modlich O, et al. Predictive biological markers for response of invasive breast cancer toanthracycline/cyclophosphamide-basd primary (radio-) chemotherapy. Anticancer Res ,2005,25 (6C):4615
  • 3Kariya S,Ogaway Y,Nishioka A, et al. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemtherapy in invasive breast cancer patients. Radiat Med ,2005,23 (3): 189
  • 4Learn PA, Yeh L, McNutt M, et al. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in operable breast cancer. Paper presented at:41th Annual Meeting of the American Society of Clinical Oncology,2005, Orlando,Florida. Abstract 9569
  • 5Munoz-Gonzalez D, Zeichner-Gancz I, Candelaria M, et al.Her-2/neu expression as a predictive factor for response to anthracycline-based chemotherapy in a mexican population of locally advanced breast cancer patients. Med Onl, 2005,22(1):23
  • 6Petit T, Borel C, Ghnassia TP, et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res,2001,7(6):1577
  • 7Kaufman M, Klinga K, Runnembaum M,et al. In vitro anthracycline sensitivity test and hormonal receptors in primary breast cancer. Cancer, 1980,47:2797
  • 8Faneyte IF, Schrama JG, Peterse JL, et al. Breast cancer response to neoadjuvant chemotherapy:predictive markers and relation with outcome. Br J Cancer,2003,88(3):406
  • 9Colleoni M, Orvieto E, Nole F, et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer, 1999,35 (4): 574
  • 10Ogston KN, Miller ID, Schofield AC, et al. Can patients'likelihood Of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment? Breast Cancer Res Treat ,2004,86: 181

同被引文献18

引证文献1

二级引证文献6

中国实用内科杂志
2007年 第24期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部